Here's Why Hold Strategy Is Apt for Core Laboratories Stock for Now
CLB benefits from long-term industry investments and strong acquisitions, though its growth is modest and vulnerable to macroeconomic and geopolitical uncertainties.
Core Laboratories Inc. (CLB) Q3 2025 Earnings Call Transcript
Core Laboratories Inc. (NYSE:CLB ) Q3 2025 Earnings Call October 23, 2025 8:30 AM EDT Company Participants Lawrence Bruno - Chairman of the Board, CEO, President & COO Gwendolyn Schreffler - Senior Vice President of Corporate Development & Investor Relations Chris Hill - Senior VP & CFO Conference Call Participants John Daniel - Daniel Energy Partners, LLC Presentation Operator Good day, and welcome to the Core Laboratories Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
Strength Seen in Core Laboratories (CLB): Can Its 6.0% Jump Turn into More Strength?
Core Laboratories (CLB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Core Laboratories Stock Rebounds in a Month: Is it Time to Buy?
CLB stock rebounds with 13% gains in a month, outpacing peers and the energy sector as revenues, margins and cash flow strengthen.
Core Laboratories: Not a Buy Yet, But Still Worth Holding On
CLB expands globally with new tech labs and energy transition projects while reducing debt but faces tariff pressures, U.S. market softness and demand volatility risks.
Core Laboratories Q2 Earnings Beat Estimates, Expenses Increase Y/Y
CLB's second-quarter earnings beat estimates. However, it declined year over year due to the underperformance of the Reservoir Description segment.
Core Laboratories Inc. (CLB) Q2 2025 Earnings Call Transcript
Core Laboratories Inc. (NYSE:CLB ) Q2 2025 Earnings Conference Call July 24, 2025 8:30 AM ET Company Participants Christopher Scott Hill - Senior VP & CFO Gwendolyn Y. Gresham - Senior Vice President of Corporate Development & Investor Relations Lawrence V.
Core Laboratories (CLB) Beats Q2 Earnings and Revenue Estimates
Core Laboratories (CLB) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.22 per share a year ago.
Watch These 4 Energy Stocks for Q2 Earnings: Beat or Miss?
Here's a preview of what to expect from energy stocks EQNR, CLB, OII and PTEN ahead of their quarterly earnings reports, set to be released tomorrow.
Core Laboratories to Post Q2 Earnings: Key Metrics to Watch
CLB's second-quarter revenues are likely to have declined from the year-ago period's level due to weak segment revenues.
Core Lab Stock Plunges 22% in Six Months: Time to Hold or Sell?
CLB struggles with declining revenues, geopolitical risks, margin compression and weak U.S. demand, creating uncertainty around growth and profitability prospects.
Core Laboratories: Better Without Its Non-Core?
Core Laboratories trades near five-year lows but suffers from limited investor interest and unclear financial segment breakdowns, despite global diversification and energy transition exposure. Reservoir Description is the standout segment, offering recurring, high-margin services with long-term demand, especially as energy transition projects like CCS gain traction. Production Enhancement faces high competition and low margins, and the company's lack of transparency and communication limits investor confidence and potential re-rating.
